Chinese Japanese Germany Korea


Treatment Drugs of Type 2 Diabetes Market and Risk Synthesis Method
Saxagliptin structure
Chemical Name:
Onglyza;BMS 477118;Saxagliptin;Saxagliptin API;Saxagliptin HCl;Saxagliptin 15ND2;Saxagliptin, >=98%;Saxagliptin-13C-d2 HCl;Saxagliptin(BMS 477118);Saxagliptin Onglyza BMS 477118
Molecular Formula:
Formula Weight:
MOL File:

Saxagliptin Properties

Boiling point:
548.7±35.0 °C(Predicted)
Flash point:
  • Risk and Safety Statements
Risk Statements  28-38-41-48
Safety Statements  24/25-26-28-36/37/39
RIDADR  3077
HS Code  29339900

Saxagliptin Chemical Properties,Uses,Production

Treatment Drugs of Type 2 Diabetes

Shacketine is a type 2 diabetes drug that can stimulate the pancreas to produce more insulin after the meal. It was reached by the cooperation of AstraZeneca and Bristol-Myers Squibb Company and belongs to DPP-IV inhibitor. It plays the role through inhibiting GLP-l degradation. GLP-I is the hormones naturally produced in the intestine after taking food. It can regulate the secretion of insulin and strengthen the utilization of glucose in the peripheral tissues. The single medication of Shacketine can improve blood glucose control and the combined medication of Shacketine with metformin, sulfonylurea and thiazolidinediones can enhance curative effect. It leads to low risk of hypoglycemia and its adverse reactions are similar to placebo, showing better tolerance.
On July 31, 2009, Shakleitine tablets (Onglyza), a new drug of type 2 diabetes, jointly researched and developed AstraZeneca and Bristol-Myers Squibb was approved by the US FDA. It can be taken once a day to treat type 2 diabetes combined with controlling Diet and exercise. The most common side effects are upper respiratory tract infections, urinary tract infections and headaches. And other side effects include allergic reactions, such as rash and urticaria.

Market and Risk

Saxagliptin (rINN), previously identified as BMS-477118, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. In June 2008, it was announced that Onglyza would be the trade name under which saxagliptin will be marketed.
In April 2016, the U.S. FDA added a warning about increased risk of heart failure.This was based on data in an article that concluded "DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes."
Saxagliptin is used as monotherapy or in combination with other drugs for the treatment of type 2 diabetes. There is no evidence to decrease the risk of heart attacks or strokes.It increases the risk of hospitalization for heart failure by about 27%. Like other DPP-4 inhibitors, it has relatively modest HbA1c lowering ability, is associated with a relatively modest risk of hypoglycemia, and does not cause weight gain.

Synthesis Method

First synthesize the precursor 109 from 1-adamantanecarboxylic acid and then synthesize the precursor 113 from Boc-L pyroglutamic acid ethyl ester. Finally synthesize Shakleitine from 109 and 113.
reaction of synthesizing Shakleitine
Figure 1 the chemical reaction of synthesizing Shakleitine.

Chemical Properties

White Solid


Saxagliptin is a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration an d has a pharmacokinetic profile compatible with once daily dosing.


ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-amino(3-hydroxyadamantan-1-yl)acetic acid with the amino group of (1S,3S,5S)-2-azabicyclo[3.1.0]hex ne-3-carbonitrile. Used in its monohydrate form for the treatment of Type II diabetes.

Saxagliptin Preparation Products And Raw materials

Raw materials

Preparation Products

Saxagliptin Suppliers

Global( 193)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86-571-85864795 China 19923 60
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21806 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 22631 55
Shanghai Time Chemicals CO., Ltd.
+86-021-57951555 CHINA 1365 55
Hangzhou FandaChem Co.,Ltd.
0086 158 5814 5714 (Mobile
+86-571-56059825 CHINA 3159 55
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 CHINA 24697 60
career henan chemical co
+86-371-86658258 CHINA 30052 58
0086-13720134139 CHINA 969 58
08657186217390 CHINA 309 58
Chemwill Asia Co.,Ltd.
86-21-51861608;;; CHINA 23979 58

View Lastest Price from Saxagliptin manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2020-03-05 Saxagliptin
US $1.00 / KG 1KG 99% 200kgs Career Henan Chemical Co
2019-07-17 Saxagliptin
US $1.00 / Kg/Drum 1KG 99% 9999tons Shandong Kangmailin Chemical Technology Co. Ltd..
2018-08-06 Saxagliptin
US $1.00 / KG 1KG 98% 1 career henan chemical co

361442-04-8(Saxagliptin)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved